ebook: Current and emerging strategies for engineered cell therapies: cancer immunotherapy
Supported by:
Published: 19 October 2022
Share this post
- Like
- Digg
- Del
- Tumblr
- VKontakte
- Buffer
- Love This
- Odnoklassniki
- Meneame
- Blogger
- Amazon
- Yahoo Mail
- Gmail
- AOL
- Newsvine
- HackerNews
- Evernote
- MySpace
- Mail.ru
- Viadeo
- Line
- Comments
- Yummly
- SMS
- Viber
- Telegram
- Subscribe
- Skype
- Facebook Messenger
- Kakao
- LiveJournal
- Yammer
- Edgar
- Fintel
- Mix
- Instapaper
- Copy Link
This exclusive ebook takes an in-depth look at recent developments in the field of cancer immunotherapy, with expert interviews exploring how researchers are advancing next-generation cell therapies into the clinic.
Innovative cell therapy development has shaped the way that cancer is treated, with chimeric antigen receptor (CAR) T-cell therapy taking a leading role. Progress in this area is ongoing and scientists around the world are focusing on improving immuno-oncology platforms, to treat as many patients as possible.
This ebook explores some of the most interesting work happening in immuno-oncology. In interviews and Q&As, experts in the industry explore CAR T-cell therapy, how some of the challenges of this platform can be overcome, how other formats of cell therapy could help cancer patients and why researchers should focus on developing next-generation immunotherapies.
Included in this ebook:
- Improving cellular therapies
Victoria Rees, Drug Target Review - Next-generation CAR T cells
Dr John Maher, Leucid Bio - Allogeneic CAR T-cell therapy: the future of cancer care
Dr Devon Shedlock. Poseida Therapeutics - The advantages of gamma-delta T-cell therapy
Dr Michael Leek, TC BioPharm - Developing state-of-the-art CAR T-cell therapy for cancer treatment
Dr Frank Neumann, Kite Pharma - The next wave: going beyond CAR T cells with cell-based therapies
Dr Daniel Teper, Cytovia Therapeutics
Dr Chris Arendt, Takeda